Member Info for CHELSEA7

Well done Ray, Liverpool away and now Fulham away, you mut be proud man ATM.

As for the headline wel i have lived int he North, Newcastle and 12 years in Liverpool, went to chool in Bournemouth and lived in BRIGHTON for 3 yers after living in three continents for 6 years. Ech place is so different in its own little ways and I am glad I have seen so much in a short like, coming up to 64 years now. Funny enough my mot sucesful years were in Liverpool, an adopted scouser I was.

So what of this week guys?? We were holding the 15s pretty well until late last week but chileed, on each visit from 18 to 10.8 and 17 to 11 we have bounced back wll each time just needed a spark to light the fire, hoping for those who traded this well it is time to open new trades, evenif just a 10k and 11.699 tranch I sold pretty well, back to my 250k target, and will be a while till I buy any or sell anymore more. It has only been a short time since Redmile and Vulpes have taken their latest positions, and I am satisfied they were not expecting mega news ubtil early 2021,so itting here oatiently and grteful I D=d get to that 250k target, it was"t easy.

Lets hope for a quick rebound from last week this coming week, and hope everyone is doing as well as they can. ATB

Absolutely C11, particularly prevalent when the SP is retreating, waiting for their top ups from the shares they have unloaded, and the personal attacks about those not declaring any sells they might have made.

And these are the same people that never declare any buys or sells, so in retrospect they can never be wrong.

Yawn,................Well it seems the MMs might just be coming to the point where PIs see a return on their next trade, and the process continues, as it always does. Have a good weekend, I think tomorrows game v Luton might just be less stressful to watch than the last months servings, lol. Enjoy

C11, no chance of that mate, they will twist your words, insinuate what you never said or meant.

Three usernames........1 person, I hear they have all had there abusive posts to me deleted this week, fortunately we have got to the warning stage, now, posts deleted, bans pit in place and the next stage.................another username will be ready to replace the banned one. ATB Buddy

Morning cleanerworld, that just about sums it up, and it has largely been the way for 2/3 weeks now. Yesterday was one of the first days we did actually tick down regardless of the daily UT trades that have been showing small rises and losses.

I used the words closely managed last week, which was to explain what you have observed. ATB

How are we all doing out there?? As well as we can be I hope.

Didn"t realise we had fallen to 15/15.50 until now yesterday, at least presumably we start blue because of correcting the SP after a UT finish.

Talking of which we have seen endless amounts of UTs in the past couple of weeks, just wondering why all of a sudden we are seeing so many for such tiny amounts??

Added Strong Buy into my Opinion box, as I feel news is very close, and should apply at any time this year of all.

Have a good day all.

cont:(.......Lander does, however, have the ability to deal with big projects, and, with herd immunity to create with vaccinations, his help here could reshape how the pandemic is tackled and eventually ended.

Biden also brings on board Frances Arnold, Ph.D., and Maria Zuber, Ph.D., who will serve as the external co-chairs of PCAST. An expert in protein engineering, Arnold is the first American woman to win the Nobel Prize in chemistry. Zuber, an expert in geophysics and planetary science, is the first woman to lead a NASA spacecraft mission and has chaired the National Science Board. They are the first women to serve as co-chairs of PCAST and form part of Biden’s wider attempt to create a more diverse and inclusive administration.

Francis Collins, M.D., meanwhile, stays on as director of the National Institutes of Health. It also looks more and more likely that FDA stalwart Janet Wood****, M.D., who has been director of the Center for Drug Evaluation and Research (but recently more focused on COVID-19 projects), will become the full-time FDA commissioner.

RELATED: Wood**** to step up to interim FDA chief as she and Sharfstein are vetted for permanent job: reports

These picks and the major backing of science in general serves as a deliberate break from the Trump administration, which many in the scientific community saw as being anti-science. Bio Twitter let out a collective sigh of relief with these statements, but the hard work has barely begun.

There will be many more infections, deaths and long-term illness from COVID-19 before the major vaccination effort is completed; having the right people in place will serve to speed things up and make things run more smoothly, but the task ahead is daunting.

Biden, who has now had two doses of a COVID-19 vaccine, will likely be reminded over this term about how quickly pharma jumped in to save the country, the economy and the world,

During the annual J.P. Morgan healthcare conference last week, biopharma execs made it clear to Fierce Biotech that, while they will not be lording this over the government, it certainly will be a factor going forward.

Reminders over this, especially from the likes of Pfizer and others who didn’t get, or were not offered, government cash for their COVID-19 work, will likely be cropping up if Biden decides to crack down on drug pricing, for instance.

While some have done it alone, Biden could also remind the industry of the billions of dollars having been thrown at Operation Warp Speed—the project designed to speed up new vaccines and treatments for COVID-19—and many of these companies have delivered, including Moderna and its mRNA vaccine, which got a swift authorization at the end of 2020 in the U.S.

Warp Speed will, by all accounts, be reshaped by the Biden team with a new name and new leadership under former FDA chief David Kessler, M.D. The legacy of Warp Speed will remain controversial, and Biden will want to take this project and ramp up i

The November election now seems such a long time ago: It has, in fact, been less than three months, but that time has been filled with political and scientific catastrophes that will shape President Joe Biden’s term in office.

The pandemic still rages on in the U.S. Whether this is a second wave, a third wave or a continuation of the first, there have been at least 400,000 deaths, and more than 3,000 people are dying every day from COVID-19, stats that blight an nation that has seen 24 million already infected.

The incoming Biden team has admonished outgoing President Donald’s Trump response, which has not favored masks or lockdowns and pushed for some drugs and treatments that proved of little efficacy. Trump’s own diagnosis and hospitalization with the disease in October served as a real low point.

Biden is coming in with COVID-19 top of the agenda. He is seeking to making 100 million shots against COVID-19 available in his first 100 days (though the exact logistics of this are not fully clear), and he has assembled a team of scientists to help lead the response, intentionally putting science first.

Biden is set to make Human Genome Project head Eric Lander, Ph.D., presidential science adviser as well as his nominee for director of the Office of Science and Technology Policy.

This will “task him to work broadly and transparently with the diverse scientific leadership of American society and make recommendations on how the Biden-Harris administration can harness the full power of science and technology on behalf of the American people,” the administration said in a statement ahead of the inauguration.

This has not always been a highly visual position, but now, for the first time, the role will be elevated to cabinet level. “Science will always be at the forefront of my administration and these world-renowned scientists will ensure everything we do is grounded in science, facts, and the truth,” Biden said.

“Their trusted guidance will be essential as we come together to end this pandemic, bring our economy back, and pursue new breakthroughs to improve the quality of life of all Americans. Their insights will help America chart a brighter future, and I am grateful they answered the call to serve.”

The nomination of genome sequencing pioneer and Broad Institute alum Lander has generally been taken as a positive move by Biden, though he is not without baggage. A few years ago, he wrote a paper about the invention of genome-editing platform CRISPR but downplayed the role of two of the key female scientists involved in its creation, causing a major backlash.

This also serves, as do many in Biden’s administration, as another former Barack Obama pick, as during his administration Lander also served as the co-chair of Obama’s President's Council of Advisors on Science and Technology (PCAST).

Chelsea,

I did say the title of the application was 'Immunotherapy' but don't think I mentioned ImmunoBody. I haven't gone back to check though.

I haven"t checked either Bermuda, had a really busy few days here, shame is I can rely on my memory less and less these days, but you are probably right, just how I read it.

From recent history we seem to have received news just about every month for many months, would expect this month to be no different, lets face it many issues are being dealt with at this time, so news could be expected on any of those at any time. Looking forward to hearing the latest for sure.

Bermuda, maybe it is me but I am sure when you first mentioned it you said under the Immunobody platform? That is why I thought it might be about Covidity.

Come to think about it, there must be a mighty move towards other infectious conditions and chronic illnesses to, as mentioned by David Evans at the 2013 AGM in London??

At 15.60, looks like a buy to me.

Another UT Trade about 1.5k at 16p showing us as up 3.90%

Anybody else with level 2?? Just feels to me that apart from not bringing us down, MMs are trying to push us back up to Full Ask at 16p. Anybody??

Buys 107k

Sells 125k..................and just 23 trades, tiny spread 15.50/15.60

Bermuda, thanks. Yeah that was my point in my post, I feel no rush to get news, I am not an all out trader, and all the good things that must be happening to get the investment we did, will be carrying on in the background.

I hear that VAL RNSed a Patent Approval today and something else, we just RNS when there is something very important to say, so I will happily sit patiently until we do.

Anything interesting that we have missed here Bermuda??

Lovejoy, always, lol. ATB

Bermuda, afternoon to you, you advised us a couple of weeks ago of a new Patent application we have made.

Presumably it is to do with the COVID platform? Do you know anything more about it?? We seem to be in no rush to announce it. Take Care.

Lovejoy, sorry to hear that, yeah I am really worried about this lady, she has been awesome to me for years and is our Scheme Manager for assisted living where I live. Guess we can all just wish everybody well, and take time out to check our own mortality levels and be aware at all times. Welcome to the BB, buddy.

C11, We can only dream my friend, I found the Fulham game so hard to watch!! But yes an early RNS would be very welcome.

I just keep reminding myself it hasn"t been very long since the huge cash injection, the new appointments and it was only the 18th December we decided in the RNS of the Covid candidate. In the meantime we seem very range bound (famous last words!!) MMs in no rush to bring us further down and all the reasons I felt so comfortable here still stand IMHO. Yeah keep smiling, and lets be grateful for the small things that matter so much. ATVB

15.50/16

A pleasent day here in N.London, but another close girlfriend has fallen foul of Covid19, early 40s and been diagnosed with leaking heart valves too.

I guess I am just so grateful I have isolated these past 4 months (well a year really) hoping you guys are well too, and those who are not, do recover well.

A few buys coming in now, a tiny spread 15.50/15.60, more importamtly, stay safe all...................ATVB.............C7

From 08.26 at full ask

cont:( Professor Lindy Durrant, Chief Scientific Officer of Scancell commented:



"We are very excited about our SN14 second generation COVID-19 vaccine which could have significant advantages over first generation vaccines, either on its own or in combination with other vaccines to broaden and strengthen the immune response for long term protection.

Well as a shareholder I am very excited too!!!

Always seems like an age before news, but it was only a few weeks ago we heard about the huge raising from Redmile and Vulpes, and 2 very senior positions filled. The last COVID update was only on the 18th December 2020, just a reminder......

18 December 2020



Scancell Holdings plc

("Scancell" or the "Company")



Scancell announces selection of COVID-19 vaccine candidate, SN14



SN14 offers several potential advantages over currently approved and late-stage COVID-19 vaccines



Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies is pleased to announce that they have selected their COVID-19 vaccine candidate, SN14, for further development and clinical trials. SN14 targets both the SARS-CoV-2 nucleocapsid (N) protein and the key receptor-binding domain (RBD) of the spike (S) protein, and is based on a modification of Scancell's ImmunoBody® DNA vaccine technology.



Fifteen vaccine candidates containing different S and N components combined with a variety of targeting technologies were evaluated for the best T cell and antibody responses. SN14 reproducibly elicited high-titre anti-S virus neutralising antibodies (VNAbs) together with high avidity T cells against both the S and N proteins. SN14 also incorporates Scancell's AvidiMab™ technology to further enhance this immune response demonstrating the broad potential of this platform technology to generate improved vaccines for both infectious diseases and cancer.



SN14 is a second generation vaccine which offers several potential advantages over currently approved and late-stage COVID-19 vaccines:

· Not only does SN14 target the S protein to induce VNAbs that prevent the COVID-19 virus from entering cells but also induces strong T cell responses to both the S and N proteins to destroy virally-infected cells and prevent further viral replication.

· As the N protein is well-conserved between coronaviruses, the SN14 vaccine has the potential to be effective against any variant or new strain of coronavirus in addition to the current COVID-19 strain.

· Use of the AvidiMab™ technology increases the potency of the T cell response which, in turn, should lead to long-term protection and immunological memory.

· DNA vaccines are exceptionally stable, do not require ultra-low temperature storage and are manufactured using relatively simple processes.



As reported in October 2020, Scancell entered into a collaboration with Cobra Biologics, part of the Cognate BioServices family, to conduct preliminary work leading to the manufacture of SN14 with the goal of starting a Phase 1 COVIDITY clinical trial as soon as possible during 2021. The project is funded by an Innovate UK grant awarded to a consortium between Scancell, the University of Nottingham and Trent University.



Professor Lindy Durrant, Chief Scientific Officer of Scancell commented:



"We are very excited about our SN14 second generation COVID19 vaccine which